- Market Capitalization, $K 12,375,900
- Shares Outstanding, K 687,550
- Annual Sales, $ 6,100 M
- Annual Income, $ 706,570 K
- 60-Month Beta 0.59
- Price/Sales 1.99
- Price/Cash Flow 10.06
- Price/Book 1.58
|Period||Period Low||Period High||Performance|
| || |
+2.84 (+18.73%)since 03/09/21
| || |
-1.60 (-8.16%)since 01/08/21
| || |
-1.77 (-8.95%)since 04/09/20
, /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange...
, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's...
, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of innovative diagnostic solutions, today...
The report for Myasthenia Gravis Treatment offers an assiduous analysis of contemporary market trends, driving factors, consumer behavior, key player strategies, product usage and brand positioning. The...
, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people...
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P y NASDAQ: GRFS), a global leader in plasma-derived therapies with a more than 100-year track record of contributing to the health and well-being of people,...
, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers,...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
|Biotechnology Index NYSE ETF|
|Defiance Nasdaq Junior Biotechnology ETF|
|Nasdaq Biotechnology Ishares ETF|
|SPDR Kensho & New Economies Composite ETF|
|Deltashares S&P Intl Managed Risk ETF|
|3rd Resistance Point||18.66|
|2nd Resistance Point||18.35|
|1st Resistance Point||18.17|
|1st Support Level||17.68|
|2nd Support Level||17.37|
|3rd Support Level||17.19|